The Drug Enforcement Administration has extended for one year the temporary placement into schedule I of the Controlled Substances Act the synthetic opioid N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-Nphenylpropionamide, also known as N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide (beta-hydroxythiofentanyl), and its isomers, esters, ethers, salts, and salts of isomers, esters and ethers.
As a result, effective through May 12, 2019, beta-hydroxythiofentanyl will remain subject to the regulatory controls and administrative, civil, and criminal sanctions applicable to the manufacture, distribution, reverse distribution, importation, exportation, research, conduct of instructional activities and chemical analysis, and possession of schedule I controlled substances.
The DEA has also issued a proposed rule that would permanently place this product into schedule I. Comments are due by June 14.
Copyright © 2021 Sandler, Travis & Rosenberg, P.A.; WorldTrade Interactive, Inc. All rights reserved.